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Background: The decision to use Palliative Sedation (PS) in terminal cancer patients 
involves difficult ethical decisions to the health professional alongside the involvement of 
the patient, family and multidisciplinary team.The purpose of the study wastoidentify the 
symptoms that often justify the use of PS; and to analyze the pharmacological strategies 
used in PS. Methods: Integrative review in the follow databases: Pubmed, ISI Web of 
Knowledge and Academic Search Complete. The keywords used were "Palliative 
Sedation"; "Palliative Care" and "End-of-life." We defined as inclusion criteria articles in 
English literature; published from 2010 to 2014, existing full-text, with references available 
and analyzed by experts. Results: Among of 45 articles found in the searched databases, 
only 13 were selected due to the suitability and relevance to the theme. Female gender 
was 55%; and the mean age, 63 (SD +/- 8) years. The symptoms which often justify the 
use of PS were pain (55%), nausea and vomiting (42.2%), loss of welfare sensation (40%), 
fatigue (35%), dyspnea (37%); delirium (31%), psychological distress/distress (24.6%). The 
results revealed that PS is normally administered in cases of refractory and intolerable 
suffering. The main drugs used were midazolam (59.7%); haloperidol (35%), 
chlorpromazine (32%), opioids (11%); metotrimeprazine (3%); propofol (1%); phenobarbital 
(1%), other benzodiazepines (22%) and other drugs (21%). The median survival of patients 
sedated ranged from 7 to 36.5 days; and non-sedated, 4 to 39.5 days. Conclusions: In the 
palliative care framework, when used properly, PS is not associated with shortening of life. 
We observed that midazolam is used as a first-line drug in PS, followed by haloperidol. 
Opioids alone should not be used for this purpose. Taking in account the PS clinical 
decision, it is evident that the main challenge for health professionals is the adoption of 
active role as members of a multidisciplinary team to provide an improved health care. The 
patient should be previous involved in the decision-making and it should be subjected to an 
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